Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Gastroenterologie
Erschienen in:

13.02.2019 | Chronisch-entzündliche Darmerkrankungen | Schwerpunkt

Geschlechtsspezifische Unterschiede bei chronisch-entzündlichen Darmerkrankungen

verfasst von: PD Dr. I. Blumenstein, Prof. Dr. B. Siegmund, Dr. E. Sonnenberg

Erschienen in: Die Gastroenterologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Übersichtsarbeit gibt einen Überblick über die aktuelle Studienlage zu geschlechtsspezifischen Unterschieden in der Behandlungsrealität von Patienten mit chronisch-entzündlichen Darmerkrankungen. Hierbei wird auf den Krankheitsverlauf, die medikamentöse und chirurgische Therapie, psychosoziale Unterschiede sowie auf Besonderheiten der medikamentösen Therapie in Schwangerschaft und Stillzeit eingegangen.
Literatur
1.
Hausmann J, Blumenstein I (2015) Gender differences and inflammatory bowel disease. Z Gastroenterol 53(8):774–778PubMedCrossRef
2.
Brahme F, Lindstrom C, Wenckert A (1975) Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmo, Sweden. Baillieres Clin Gastroenterol 69(2):342–351
3.
Kyle J (1992) Crohn’s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Baillieres Clin Gastroenterol 103(2):392–399
4.
Latour P, Louis E, Belaiche J (1998) Incidence of inflammatory bowel disease in the area of Liege: a 3 years prospective study (1993–1996). Acta Gastroenterol Belg 61(4):410–413PubMed
5.
Leong RW, Lau JY, Sung JJ (2004) The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 10(5):646–651PubMedCrossRef
6.
Ng SC et al (2013) Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 62(4):630–649PubMedCrossRef
7.
Shivananda S et al (1987) Epidemiology of Crohn’s disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Baillieres Clin Gastroenterol 93(5):966–974
8.
Wagtmans MJ et al (2001) Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol 96(5):1541–1546PubMedCrossRef
9.
Yang SK, Loftus EV Jr., Sandborn WJ (2001) Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 7(3):260–270PubMedCrossRef
10.
Virta L et al (2012) Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease—a nationwide, register-based finnish case-control study. Am J Epidemiol 175(8):775–784PubMedCrossRef
11.
Shaw SY, Blanchard JF, Bernstein CN (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105(12):2687–2692PubMedCrossRef
12.
Andersson RE et al (2003) Appendectomy is followed by increased risk of Crohn’s disease. Baillieres Clin Gastroenterol 124(1):40–46
13.
14.
Lakatos PL et al (2013) Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 19(5):1010–1017PubMedCrossRef
15.
Biedermann L et al (2015) High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation—data from the Swiss IBD cohort study. J Crohns Colitis 9(10):819–829PubMedCrossRef
16.
Fraga M et al (2017) Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol 29(1):91–97PubMedCrossRef
17.
Ampuero J et al (2014) Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol 29(2):291–295PubMedCrossRef
18.
Greenstein AJ et al (1992) Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 71(5):261–270CrossRef
19.
Wu XR et al (2013) Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 7(5):e171–7PubMedCrossRef
20.
Vavricka SR et al (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18(3):496–505PubMedCrossRef
21.
Lee DW et al (2017) Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol 23(35):6474–6481PubMedPubMedCentralCrossRef
22.
Romberg-Camps MJ et al (2009) Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 104(2):371–383PubMedCrossRef
23.
Mazor Y et al (2011) Prediction of disease complication occurrence in Crohn’s disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis 5(6):592–597PubMedCrossRef
24.
Blumenstein I et al (2011) Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 5(3):203–210PubMedCrossRef
25.
Bokemeyer B et al (2013) Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 7(5):355–368PubMedCrossRef
26.
Wada Y et al (2015) Risk factors for decreased bone mineral density in inflammatory bowel disease: a cross-sectional study. Clin Nutr 34(6):1202–1209PubMedCrossRef
27.
Walldorf J et al (2013) Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis 7(11):901–907PubMedCrossRef
28.
Bartram SA et al (2006) Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 12(35):5680–5686PubMedPubMedCentralCrossRef
29.
Robinson RJ et al (1998) Osteoporosis and determinants of bone density in patients with Crohn’s disease. Dig Dis Sci 43(11):2500–2506PubMedCrossRef
30.
Soderlund S et al (2010) Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Baillieres Clin Gastroenterol 138(5):1697–1703
31.
Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10(6):639–645PubMedCrossRef
32.
Bessissow T et al (2013) Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. J Crohns Colitis 7(11):e580–e587PubMedCrossRef
33.
Thukkani N, Williams JL, Sonnenberg A (2011) Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis 17(6):1333–1337PubMedCrossRef
34.
Koido S et al (2014) Factors associated with incomplete colonoscopy at a Japanese academic hospital. World J Gastroenterol 20(22):6961–6967PubMedPubMedCentralCrossRef
35.
Rimola J et al (2009) Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics 29(3):701–719PubMedCrossRef
36.
Caso V et al (2010) Gender differences in patients with acute ischemic stroke. Womens Health (Lond) 6(1):51–57CrossRef
37.
Shaw LJ et al (2008) Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 117(14):1787–1801PubMedCrossRef
38.
Lesuis N et al (2012) Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 10:82PubMedPubMedCentralCrossRef
39.
40.
Szalat A, Raz I (2008) Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 10(12):1135–1156PubMed
41.
Schmetzer O, Florcken A (2012) Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol 2012(214):411–442
42.
Billioud V, Sandborn WJ, Peyrin-Biroulet L (2011) Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106(4):674–684PubMedCrossRef
43.
Sprakes MB et al (2012) Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experience. J Crohns Colitis 6(2):143–153PubMedCrossRef
44.
Zelinkova Z et al (2012) Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol 18(47):6967–6973PubMedPubMedCentralCrossRef
45.
Lie MR, Kreijne JE, van der Woude CJ (2017) Sex is associated with adalimumab side effects and drug survival in patients with Crohn’s disease. Inflamm Bowel Dis 23(1):75–81PubMedCrossRef
46.
Hawthorne AB, Rubin G, Ghosh S (2008) Review article: medication non–adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 27(12):1157–1166PubMedCrossRef
47.
Long MD et al (2012) Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 18(11):2099–2106PubMedCrossRef
48.
Mantzaris GJ et al (2007) How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission? Inflamm Bowel Dis 13(4):446–450PubMedCrossRef
49.
Yen L et al (2012) Medication use patterns and predictors of nonpersistence and nonadherence with oral 5‑aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm 18(9):701–712PubMed
50.
Zelante A et al (2014) Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol 60(4):269–274PubMed
51.
Lopez A et al (2013) Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 19(7):1528–1533PubMedCrossRef
52.
Peyrin-Biroulet L et al (2012) Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol 107(11):1693–1701PubMedPubMedCentralCrossRef
53.
Hofer B et al (2001) The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology 48(37):152–155PubMed
54.
De Cruz P et al (2015) Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients—a POCER study analysis. Aliment Pharmacol Ther 42(7):867–879PubMedCrossRef
55.
Samuel S et al (2013) Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 19(9):1858–1866PubMedPubMedCentral
56.
Targownik LE et al (2012) The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 107(8):1228–1235PubMedCrossRef
57.
Rottoli M et al (2012) Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Dis 14(3):336–341PubMedCrossRef
58.
Wu XR et al (2016) Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg 20(3):631–639PubMedCrossRef
59.
Sewitch MJ et al (2001) Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 96(5):1470–1479PubMedCrossRef
60.
Slonim-Nevo V et al (2018) Effect of social support on psychological distress and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis 24(7):1389–1400PubMedCrossRef
61.
Fuller-Thomson E, Sulman J (2006) Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 12(8):697–707PubMedCrossRef
62.
Hauser W et al (2011) Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 17(2):621–632PubMedCrossRef
63.
Nahon S et al (2012) Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 18(11):2086–2091PubMedCrossRef
64.
Panara AJ et al (2014) The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther 39(8):802–810PubMedCrossRef
65.
Maunder RG et al (1997) Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol 11(8):681–685PubMedCrossRef
66.
Graff LA et al (2006) The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 4(12):1491–1501PubMedCrossRef
67.
Hauser G et al (2011) Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol 35(Suppl 2):203–207PubMed
68.
Nurmi E et al (2013) The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol 48(1):51–57PubMedCrossRef
69.
McDermott E et al (2015) Body image dissatisfaction: clinical features, and psychosocial disability in inflammatory bowel disease. Inflamm Bowel Dis 21(2):353–360PubMedCrossRef
70.
71.
Allocca M et al (2018) Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol 30(3):316–322PubMedCrossRef
72.
Heetun ZS et al (2007) Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 26(4):513–533PubMedCrossRef
73.
Mountifield R et al (2009) Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 15(5):720–725PubMedCrossRef
74.
Feagins LA, Kane SV (2009) Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 104(3):768–773PubMedCrossRef
75.
de Lima A et al (2016) Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 14(9):1285–1292PubMedCrossRef
76.
Sands K et al (2015) Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 41(9):821–834PubMedCrossRef
77.
Selinger CP et al (2013) Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 7(6):e206–13PubMedCrossRef
Metadaten
Titel
Geschlechtsspezifische Unterschiede bei chronisch-entzündlichen Darmerkrankungen
verfasst von
PD Dr. I. Blumenstein
Prof. Dr. B. Siegmund
Dr. E. Sonnenberg
Publikationsdatum
13.02.2019
Verlag
Springer Medizin
Erschienen in
Die Gastroenterologie / Ausgabe 2/2019
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-019-0323-8

Weitere Artikel der Ausgabe 2/2019

Erklärung zu finanziellen und nichtfinanziellen Interessen in CME-Fortbildungen von Springer Medizin

Mitteilungen des BDI

  • Mitteilungen des BDI

Neue Standards in der adjuvanten Therapie des Pankreaskarzinoms?!

CME: Diagnostik und Therapie des duktalen Adenokarzinoms des Pankreas

Diese CME-Fortbildung gibt unter Berücksichtigung der aktuellen Leitlinien einen allgemeinen Überblick zum duktalen Adenokarzinom des Pankreas und erörtert ausgewählte Aspekte der Epidemiologie, Pathogenese und Genetik sowie Grundprinzipien der Diagnostik und Therapie.

Mitteilungen Netzwerk gegen Darmkrebs

  • Mitteilungen Netzwerk gegen Darmkrebs

Überwachung der serratierten Polyposis

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Bildnachweise